

# CURRICULUM VITAE

## 1. Name

First name: ALDO	Last name: FILOSA
---------------------	----------------------

## 2. Present Position with Work Address

Position: Director of Rare Red blood cell diseases Unit	Street address or postal address: Via Antonio Cardarelli, 9
Name of institution or organization: UOSD Centro per le Microcitemie , A.O. Antonio Cardarelli	City & postal/zip code: Napoli, 80128
Start date (at least year): 2012	Country:

## 3. Main University Degree(s)

Name of university/institute: University of Naples, Federico II	Degree awarded: Medicine e Surgery degree
City & country: Naples	Year of graduation: 1985
Name of university/institu	Degree awarded:
City & country:	Year of graduation:
Name of university/institute:	Degree awarded:
City & country:	Year of graduation:

## 4. Professional Training

Name of university/institute: University of Naples, Federico II	City & country: Naples
Qualification: Paediatrician	Dates of attendance: 08 MAY 1989
Name of university/institute: University of Naples, Federico II	City & country: Naples
Qualification: Neonatologist	Dates of attendance: 29 MAY 1991
Name of university/institute: University of Naples, Federico II	City & country: Naples
Qualification: Haematologist	Dates of attendance: 21 OCT 1998

## 5. Registration/Medical License number (where applicable)

Number: NA
---------------

## 6. Previous Appointments

Position: Medical manager in Paediatric Unit	Dates: From 01-03-1991 to 26-02-2011
Institution/organization:	City & country:

## CURRICULUM VITAE

Position: Medical manager as Paediatrician and as Haematologist in Rare Red blood cell diseases Unit	Dates: 27-02-2011
----- Institution/organization:	City & country:
Position:	Dates:
----- Institution/organization:	City & country:

### 7. Clinical Research Experience (append publication list if available)

<p>Principal Investigator</p> <ul style="list-style-type: none"> <li>• Principal Investigator in the International Trial (Phase III) on the new formula of iron chelator Deferasirox by Novartis Protocol (ICL670A2409). Finished in October 2007</li> <li>• Principal Investigator in the International Trial (Phase II) on the new formula of iron chelator Deferasirox by Novartis Protocol (ICL 670A2203). Finished in October 2007</li> <li>• Principal Investigator in the International Trial (Phase II) on the new formula of iron chelator Deferasirox by Novartis Protocol (ICL670A107E). Finished in October 2007</li> <li>• Principal Investigator in the International Trial (Phase II) on the new formula of iron chelator Deferasirox by Novartis Protocol (ICL670A117). Finished in December 2007</li> <li>• Principal Investigation in the Trial for the safety and efficacy of Neridronato (Nerixia) for the treatment of osteoporosis in patients affected by thalassemia major or thalassemia intermedia</li> <li>• Principal Investigator in the Randomized clinical Trial for Deferiprone vs Deferiprone-Desferoxamina in patients with Thalassemia Major. By SoSte (Società Italiana per lo studio delle emoglobinopatie) .</li> <li>• Principal Investigator for the use of hydrossiurea in patients with Thalassemia major and genetic coumpound (Lepore, beta thalassemia) for the induction of syntesis of Hb F.</li> <li>• Principal Investigator for the randomized Protocol for sequenzial Deriprone-Deferasirox vs deferiprone or Deferasirox in patients with Thalassemia Major” Coordinator doctor A Maggio</li> <li>• Principal Investigator for National Trial for Interferon plu Ribavirin in patients with Thalassemia major and Hepatitis C virus.</li> <li>• Principal Investigator for the Trial by European Community for a Multicenter Trial (DEEP) for the use of deferipron in patients with age ranged from 1 mounth to 18 years.</li> <li>• Principal Investigator in the International Trial acceleron A0563 . A Phase 2, Open-Label, Ascending Dose Study to Evaluate the Effects of ACE-536 in Patients with <math>\beta</math>-Thalassemia (A536-04 e A536-06).</li> </ul>
--